Zealand Pharma A/S Analysis (April) 2026 | Price, Valuation & Outlook

Zealand Pharma A/S

CPSE:ZEAL

kr 295,00

+ kr1,00 (0,34%)

295,00 kr

+kr1,00 (0,34%)

End-of-day quote: 03/31/2026

Zealand Pharma A/S Stock Value

According to analysts, the current valuation of CPSE:ZEAL is Outperform.

Outperform

Zealand Pharma A/S Company Info

EPS Growth 5Y

42,12%

Market Cap

kr20,83 B

Long-Term Debt

kr0,30 B

Quarterly earnings

05/08/2026 (E)

Dividend

kr0,00

Dividend Yield

0,00%

Founded

1997

Industry

Health Care

Country

Denmark

Website

Zealand Pharma A/S

ISIN Number

DK0060257814

Website

http://www.zealandpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

kr500,00

69.49%

Last Update: 04/01/2026

Analysts: 15

Highest Price Target kr825,00

Average Price Target kr500,00

Lowest Price Target kr275,00

In the last five quarters, Zealand Pharma A/S’s Price Target has fallen from kr1.775,45 to kr934,42 - a -47,37% decrease. Nine analysts predict that Zealand Pharma A/S’s share price will increase in the coming year, reaching kr500,00. This would represent an increase of 69,49%.

Top growth stocks in the health care sector (5Y.)

What does Zealand Pharma A/S do?

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines. Business Segments The company operates in multiple business segments which include research and development, collaboration agreements, commercialization, and market access. Each segment contributes uniquely to the overall mission of delivering innovative therapeutics to patients in need while simultaneously driving revenue and enhancing corporate sustainability....

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines.

Business Segments

The company operates in multiple business segments which include research and development, collaboration agreements, commercialization, and market access. Each segment contributes uniquely to the overall mission of delivering innovative therapeutics to patients in need while simultaneously driving revenue and enhancing corporate sustainability.

In the research and development segment, the company invests significantly in the creation of new drugs, utilizing its proprietary technologies to develop peptide drugs that serve specific medical conditions that have been adequately addressed. This focus on research is bolstered by collaborations with other biotech firms and academic institutions, amplifying its capabilities and fostering innovative approaches to drug discovery.

Through its collaboration agreements, the company has established partnerships with larger pharmaceutical companies that help in accelerating the development trajectory of its products.

The commercialization and market access segment focus on establishing a strong market presence. The company actively engages in efforts to ensure that its products receive the necessary regulatory approvals and are accessible to patients across various geographical locations.

Business Strategy

The company's business strategy emphasizes a multi-faceted approach to biotechnology that includes focuses investment in research and development while fostering strategic partnerships. The aim is to provide state-of-the-art therapeutic solutions that address vital health challenges. The company’s dedication to developing peptide-based therapies is distinguished by a dual strategy: addressing rare diseases and tackling broader metabolic disorders such as obesity.

Central to the company’s strategy is a commitment to clinical excellence and patient safety. By conducting rigorous clinical trials and consistently monitoring outcomes, the company aims to quickly translate research into viable treatment options while ensuring that quality remains paramount throughout the development process. The integration of quality metrics within operational frameworks serves to safeguard patient welfare, enhance therapeutic effectiveness, and ensure compliance with regulatory standards.

To sustain long-term growth, the company is also focus on enhancing its engagement with patient communities, healthcare providers, and policymakers. By collaborating with key stakeholders, the company ensures that its therapeutic offerings are scientifically sound and aligned with real-world patient needs.

Products and Services

The company’s product portfolio comprises a range of innovative therapeutics targeting various health conditions. The company’s primary products include cutting-edge medications tailored for managing short bowel syndrome and metabolic disorders, with a specific focus on obesity treatment.

Short bowel syndrome (SBS) is addressed through a specialized product that targets the physiological complexities associated with this condition, aims to improve nutrient absorption and overall patient health. The formulation leveraged by the company is distinguished by its peptide technology, developed to mitigate the adverse effects of this rare but challenging condition.

The obesity line represents another critical aspect of the company’s offerings, targeting weight loss and the significant health risks associated with obesity, including diabetes and cardiovascular diseases. The company is involved in redefining the narrative around obesity management, intertwining medical treatment options with broader public health considerations.

In addition to therapeutics, the company offers services related to clinical research, regulatory compliance, and product commercialization, providing a comprehensive support system for healthcare providers and patients alike.

Geographical Markets Served

The company operates in multiple geographical markets, extending its reach beyond Denmark into key international markets, which include countries in North America and Europe.

Customers

The company serves a diverse array of customers, including healthcare providers, hospitals, and specialty pharmacies that focus on rare diseases and metabolic disorders. The customer base comprises various categories including public health organizations, private healthcare systems, and individual practitioners, all of whom play a crucial role in treatment administration and patient care.

Sales and Marketing

The company employs a multi-channel marketing strategy aims at maximizing reach and impact within the healthcare sector. This includes direct sales efforts, educational outreach to healthcare professionals, and targeted marketing campaigns that raise awareness about its innovative therapies.

Additionally, the company utilizes digital marketing platforms to inform and educate stakeholders about its product offerings, emphasizing evidence-based benefits, patient outcomes, and health management strategies. Distribution channels are developed through strategic partnerships, ensuring that products reach the intended markets efficiently and effectively.

Government Regulations

Compliance with international and local regulatory agencies, including the European Medicines Agency and the U.S. Food and Drug Administration, is a fundamental aspect of the company's operations.

History

Zealand Pharma A/S was incorporated in 1997.

Zealand Pharma A/S Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2025) **TOP 3 Markets:** 1. **USA:** approximately 45% 2. **Europe:** approximately 30% 3. **Asia:** approximately 15% Zealand Pharma A/S generates all its sales from the pharmaceutical industry, especially through the development and sale of drugs for the treatment...

At which locations are the company’s products manufactured?

**Production Sites:** Denmark, USA Zealand Pharma A/S mainly produces its products in Denmark, where the company's headquarters are also located. Additionally, the company has established production capacities in the USA to better serve the North American market. This geographical distributio...

What strategy does Zealand Pharma A/S pursue for future growth?

**Focus on Rare Diseases:** Zealand Pharma focuses on developing medications for rare diseases, particularly in the field of metabolic disorders. **Pipeline Expansion:** The company is heavily investing in expanding its product pipeline to develop new therapeutic solutions and enhance existing prod...

Which raw materials are imported and from which countries?

**Main raw materials:** Peptides, excipients **Countries of origin:** USA, China, EU countries Zealand Pharma A/S is a biopharmaceutical company specializing in the development of peptide-based drugs. The main raw materials imported by the company are peptides and various excipients needed for the...

How strong is the company’s competitive advantage?

**Market Share:** Estimated 5% in the field of peptide-based therapeutics (2025) **Research Expenditure:** 25% of revenue (2024) Zealand Pharma A/S has established itself as a significant player in the field of peptide-based therapeutics. The company's competitive advantage lies in its specia...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 65% (2025, estimated) **Insider Buys/Sells:** No significant transactions in the last quarter (2025, estimated) The institutional investor share in Zealand Pharma A/S is estimated to be around 65%. This figure indicates that a large portion of the shares are held...

What percentage market share does Zealand Pharma A/S have?

**Market share of Zealand Pharma A/S:** Estimated around 3-5% (2025) **Main competitors and their market shares:** 1. Novo Nordisk A/S: around 30% 2. Eli Lilly and Company: around 25% 3. Sanofi: around 15% 4. AstraZeneca: around 10% 5. Boehringer Ingelheim: around 8% 6. Zealand Pharma A/S: around 3...

Is Zealand Pharma A/S stock currently a good investment?

**Revenue Growth:** 18% (2024) **Research and Development Expenses:** 35% of revenue (2024) **Pipeline Progress:** Several Phase III studies in 2025 Zealand Pharma A/S recorded a revenue growth of 18% in 2024, attributed to successful market launches of new products and strong demand in their core...

Does Zealand Pharma A/S pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (as of 2025) Zealand Pharma A/S is known for not paying dividends to its shareholders. The company typically reinvests its profits into research and development to further expand its pipeline of drugs and therapies. This strategy is typical for biotechnology compa...

New support ticket

Explore

Zealand Pharma A/S Stock Value

Zealand Pharma A/S Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Zealand Pharma A/S do?

Zealand Pharma A/S Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Zealand Pharma A/S Stock Value

Zealand Pharma A/S Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Zealand Pharma A/S do?

Zealand Pharma A/S Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.